中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

24 records (took 0.044 seconds)

    Method for in-vivo binding of chromatin fragments
    1.
    发明授权
    Method for in-vivo binding of chromatin fragments 有权
    染色质片段的体内结合方法

    公开(公告)号：US09096655B2

    公开(公告)日：2015-08-04

    申请号：US13575756

    申请日：2011-01-24

    Applicant: Indraneel Mittra ,  Rekha Mannemcherril Ramesan ,  Chandra Prakash Sharma ,  Gopichettipalayam Subbaratnam Bhuvaneshwar ,  Kavita Anirban Pal

    Inventor： Indraneel Mittra ,  Rekha Mannemcherril Ramesan ,  Chandra Prakash Sharma ,  Gopichettipalayam Subbaratnam Bhuvaneshwar ,  Kavita Anirban Pal

    IPC: A61K47/28 ,  A61K39/44 ,  C07K16/08 ,  A61K47/48 ,  A61K39/00

    CPC classification number: C07K16/18 ,  A61K47/61 ,  A61K47/6939 ,  A61K2039/505 ,  C07K16/08 ,  Y10T428/2982

    Abstract: A process for substantially reducing levels of circulating chromatin fragments (CCFs) from a medium using binding agents such as antibodies or antibodies complexed with haemocompatible natural polymer substrates like as alginates, chitosan and pullulan to form complexed antibody-substrate nano-particulates (CNP) to bind and/or inactivate CCFs is disclosed. The amount of antibody bound to the polymer varies from 30% to 100% of activated sites in the polymer. Elevated levels of CCFs can be substantially reduced following administration of tissue damaging agents that generate apoptotic chromatin fragments by the concomitant administration of CNPs or concomitant administration of H4 antibody alone. A method of treatment is disclosed wherein therapeutic dose of CNPs, or H4 antibody alone, are administered systematically, or orally, in a delivery system to curb pathological conditions that are associated with increased burden of circulating chromatin fragments.

    Abstract translation: 使用结合剂（例如抗体或抗体与诸如藻酸盐，壳聚糖和支链淀粉等血液相容性天然聚合物底物复合的抗体）从培养基中显着降低循环染色质片段（CCF）的水平的方法，以形成复合的抗体 - 底物纳米颗粒（CNP） 公开了结合和/或灭活CCF。 与聚合物结合的抗体的量在聚合物中的活化位点的30％至100％不等。 在施用组合损伤剂后，CCF的升高水平可以显着降低，所述组织损伤剂通过伴随施用CNP或单独施用H4抗体产生凋亡染色质片段。 公开了一种治疗方法，其中治疗剂量的CNP或单独的H4抗体在递送系统中系统地或口服地施用以遏制与循环染色质片段的负担增加相关的病理状况。

    Method And System For Data Management
    3.
    发明申请
    Method And System For Data Management 审中-公开
    数据管理方法与系统

    公开(公告)号：US20090259617A1

    公开(公告)日：2009-10-15

    申请号：US12103574

    申请日：2008-04-15

    Applicant: Richard Charles Cownie ,  Chandra Prakash Jain ,  Somnath Banerjee ,  Tushar Gupta

    Inventor： Richard Charles Cownie ,  Chandra Prakash Jain ,  Somnath Banerjee ,  Tushar Gupta

    IPC: G06F17/30

    CPC classification number: G06F16/21

    Abstract: The invention provides a method, a system and a computer program product for managing the data of Electronic Design Automation (EDA) tools in data processing units. This data is managed by a database management system. Data entries that are added to a database are sorted, compressed and stored. These data entries can be easily retrieved from the database that is based on a retrieval key.

    Abstract translation: 本发明提供一种用于在数据处理单元中管理电子设计自动化（EDA）工具的数据的方法，系统和计算机程序产品。 该数据由数据库管理系统管理。 添加到数据库的数据条目进行排序，压缩和存储。 可以从基于检索关键字的数据库轻松地检索这些数据条目。

    pH SENSITIVE NANOPARTICLE FORMULATION FOR ORAL DELIVERY OF PROTEINS/PEPTIDES
    4.
    发明申请
    pH SENSITIVE NANOPARTICLE FORMULATION FOR ORAL DELIVERY OF PROTEINS/PEPTIDES 审中-公开
    用于口服递送蛋白质/肽的pH敏感纳米颗粒配方

    公开(公告)号：US20090098205A1

    公开(公告)日：2009-04-16

    申请号：US12066143

    申请日：2005-12-30

    Applicant: Chandra Prakash Sharma ,  Ramesan Rekha Mannemcherril

    Inventor： Chandra Prakash Sharma ,  Ramesan Rekha Mannemcherril

    IPC: A61K9/14 ,  A61K38/00 ,  A61K38/28

    CPC classification number: A61K9/5161 ,  A61K9/5192 ,  A61K38/28 ,  Y10S977/773 ,  Y10S977/906

    Abstract: The present invention provides a pH sensitive nanoparticulate delivery system for the administration of peptide hormones and drugs. In particular it provides a pH sensitive nanoparticulate for oral insulin administration. The nanoparticles developed by this process are fatty acid nanoparticles and a polymer is used as a stabilizer and also to incorporate pH sensitivity so that these particles shrink in the gastric acidic pH thereby protecting the incorporated insulin. These particles being also hydrophobic in nature and by virtue of their small size get absorbed through the intestinal cell wall and Peyer's patches. These nanoparticles are novel and unique in the sense that polymer content is only 0.03-0.06 g/g product and the polymer is hydrophilic in nature.

    Abstract translation: 本发明提供了用于施用肽激素和药物的pH敏感的纳米颗粒递送系统。 特别地，其提供用于口服胰岛素给药的pH敏感性纳米颗粒。 通过该方法开发的纳米颗粒是脂肪酸纳米颗粒，并且聚合物用作稳定剂并且还引入pH敏感性，使得这些颗粒在胃酸性pH中收缩，从而保护掺入的胰岛素。 这些颗粒本质上也是疏水性的，并且由于它们的小尺寸，通过肠细胞壁和派耶尔的斑块被吸收。 这些纳米颗粒是新颖独特的，因为聚合物含量仅为0.03-0.06g / g，聚合物本质上是亲水性的。

    S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders
    5.
    发明申请
    S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders 审中-公开
    S-甲基 - 二氢 - 齐拉昔酮用于治疗精神病和眼部疾病

    公开(公告)号：US20060287336A1

    公开(公告)日：2006-12-21

    申请号：US09873973

    申请日：2001-06-04

    Applicant: Chandra Prakash ,  Terese Smolarek

    Inventor： Chandra Prakash ,  Terese Smolarek

    IPC: A61K31/496

    CPC classification number: A61K31/22 ,  A61K31/496

    Abstract: This invention relates to pharmaceutical compositions containing S-methyl-dihydro-ziprasidone and to the use of such compound and its pharmaceutically acceptable salts for the treatment of psychiatric and ocular disorders. More specifically, it relates to the use of such compound and its pharmaceutically acceptable salts for the treatment of a disorder or condition selected from: schizophrenia, anxiety disorders such as generalized anxiety disorder, panic disorder, posttraumatic stress disorder and phobias (e.g., social phobia, agoraphobia etc.); psychotic episodes of anxiety: anxiety, agitation, excessive aggression, tension, or social or emotional withdrawal associated with psychosis; psychotic mood disorders such as severe major depressive disorder; mood disorders associated with psychotic disorders such as acute mania and depression associated with bipolar disorder, and mood disorders associated with schizophrenia; behavioral disturbances associated with mental retardation, autistic disorder, and conduct disorder; dementias such as dementias associated with Alzheimer's disease; drug-induced and neurodegeneration based dyskinesias; obsessive compulsive disorder; Tourette's syndrome; glaucoma; and ischemic retinopathy.

    Abstract translation: 本发明涉及含有S-甲基 - 二氢 - 齐拉西酮的药物组合物以及这种化合物及其可药用盐在治疗精神病和眼部疾病中的用途。 更具体地说，它涉及这种化合物及其药学上可接受的盐在治疗选自以下的病症或病症中的用途：精神分裂症，焦虑症例如广泛性焦虑症，惊恐障碍，创伤后应激障碍和恐惧症（例如社交恐惧症 ，广场恐怖等）; 焦虑的精神病发作：与精神病有关的焦虑，激动，过度侵略，紧张或社会或情绪退缩; 精神病心理障碍如重度抑郁障碍; 与精神病性疾病相关的情绪障碍，例如与双相障碍相关的急性躁狂症和抑郁症，以及与精神分裂症相关的情绪障碍; 与精神发育迟滞，自闭症和行为障碍相关的行为障碍; 痴呆症如与阿尔茨海默病相关的痴呆; 药物诱导和神经退行性运动障碍; 强迫症 图雷特综合征 青光眼; 和缺血性视网膜病变。

    METHOD FOR IN-VIVO BINDING OF CHROMATIN FRAGMENTS
    7.
    发明申请
    METHOD FOR IN-VIVO BINDING OF CHROMATIN FRAGMENTS 有权
    色氨酸片段的体内结合方法

    公开(公告)号：US20120301487A1

    公开(公告)日：2012-11-29

    申请号：US13575756

    申请日：2011-01-24

    Applicant: Indraneel Mittra ,  Rekha Mannemcherril Ramesan ,  Chandra Prakash Sharma ,  Gopichettipalayam Subbaratnam Vaneshwar ,  Kavita Anirban Pal

    Inventor： Indraneel Mittra ,  Rekha Mannemcherril Ramesan ,  Chandra Prakash Sharma ,  Gopichettipalayam Subbaratnam Vaneshwar ,  Kavita Anirban Pal

    IPC: A61K39/395 ,  C07K16/18 ,  A61P29/00 ,  B82Y5/00

    CPC classification number: C07K16/18 ,  A61K47/61 ,  A61K47/6939 ,  A61K2039/505 ,  C07K16/08 ,  Y10T428/2982

    Abstract: A process for substantially reducing levels of circulating chromatin fragments (CCFs) from a medium using binding agents such as antibodies or antibodies complexed with haemocompatible natural polymer substrates like as alginates, chitosan and pullulan to form complexed antibody-substrate nano-particulates (CNP) to bind and/or inactivate CCFs is disclosed. The amount of antibody bound to the polymer varies from 30% to 100% of activated sites in the polymer. Elevated levels of CCFs can be substantially reduced following administration of tissue damaging agents that generate apoptotic chromatin fragments by the concomitant administration of CNPs or concomitant administration of H4 antibody alone. A method of treatment is disclosed wherein therapeutic dose of CNPs, or H4 antibody alone, are administered systematically, or orally, in a delivery system to curb pathological conditions that are associated with increased burden of circulating chromatin fragments.

    Abstract translation: 使用结合剂（例如抗体或抗体与诸如藻酸盐，壳聚糖和支链淀粉等血液相容性天然聚合物底物复合的抗体）从培养基中显着降低循环染色质片段（CCF）的水平的方法，以形成复合的抗体 - 底物纳米颗粒（CNP） 公开了结合和/或灭活CCF。 与聚合物结合的抗体的量在聚合物中的活化位点的30％至100％不等。 在施用组合损伤剂后，CCF的升高水平可以显着降低，所述组织损伤剂通过伴随施用CNP或单独施用H4抗体产生凋亡染色质片段。 公开了一种治疗方法，其中治疗剂量的CNP或单独的H4抗体在递送系统中系统地或口服地施用以遏制与循环染色质片段的负担增加相关的病理状况。

    Artificial bidirectional promoter for activation of gene expression
    10.
    发明授权
    Artificial bidirectional promoter for activation of gene expression 有权
    用于激活基因表达的人工双向启动子

    公开(公告)号：US07390661B2

    公开(公告)日：2008-06-24

    申请号：US11542590

    申请日：2006-10-03

    Applicant: Rakesh Tuli ,  Sawant Samir Vishwanath ,  Chandra Prakash Chaturvedi ,  Kanti Kiran ,  Rajesh Mehrotra

    Inventor： Rakesh Tuli ,  Sawant Samir Vishwanath ,  Chandra Prakash Chaturvedi ,  Kanti Kiran ,  Rajesh Mehrotra

    IPC: C12N5/14 ,  C12N5/04 ,  C12N15/00 ,  C12N15/09 ,  C12N15/11 ,  C12P21/06 ,  A01H1/00

    CPC classification number: C12N15/8216

    Abstract: A bidirectional module for activation of gene expression and regulation of transcription in both directions is disclosed. The bidirectional module comprises multiple cis regulatory DNA sequence elements, strategically arranged to give a ‘Transcription Activating Module’ that achieves high level expression from a ‘Transcription Initiation Module’. The latter functions like a minimal promoter. The former activates transcription simultaneously in both the directions from the latter and also responds to several transcription inducing, external stimuli in both the directions. Since it is an artificially designed bidirectional transcription module, it has no equivalent DNA sequence in plant genome. This reduces the chances of the genes from being silenced by homology based mechanisms. A bidirectional promoter module as this, can therefore be used to develop efficient vectors for genetic engineering in plants.

    Abstract translation: 公开了用于激活基因表达和双向转录调节的双向模块。 双向模块包括多个顺式调节DNA序列元件，策略性地排列成一个“转录激活模块”，从“转录起始模块”获得高水平的表达。 后者的功能就像一个最小的启动子。 前者从后者两个方向同时激活转录，并且对两个方向的几种转录诱导，外部刺激也作出反应。 由于它是人工设计的双向转录模块，因此在植物基因组中没有等效的DNA序列。 这减少了通过基于同源性的机制使基因沉默的机会。 因此，双向启动子模块因此可用于开发植物中遗传工程的有效载体。

Patent Agency Ranking